Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2012-02-29
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In connection with mentioned above, this study is devoted to the estimation of possibility to use GerdQ in routine practice of Russian physicians.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study
NCT00963144
Validation of HRM Score for the GERD Diagnosis
NCT05851482
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
NCT00842387
The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire
NCT00901004
National Survey on GERD Patients (Adults and Children)
NCT00833573
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients of both sexes, 18 years and older
* planned esophagogastroduodenoscopy
Exclusion Criteria
* the presence of contraindications for esophagogastroduodenoscopy or pH-metry
* refusal to sign informed consent
* acceptance of antisecretory drugs (proton pump inhibitors, h2-receptor blockers), antacids and prokinetics for 7 days before enrollment
* Pregnancy
* Confirmed or suspected malignancy
* Impairment of the mental sphere
* Acceptance of nsaids (including acetylsalicylic acid at a dose of 150 mg / day), cytostatics, antibiotics (tetracyclines, lincosamides) at enrollment and during the preceding 30 days
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexey Stepanov, Prof
Role: STUDY_DIRECTOR
AstraZeneca
Vladimir Ivashkin, Prof
Role: PRINCIPAL_INVESTIGATOR
Head of Inner Disease Department of First Moscow State Medical University named after I.M. Sechenov
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research site
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-GRU-XXX-2011/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.